Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation

BACKGROUND: Tacrolimus is metabolized by cytochrome P450 (CYP) 3A4 and 3A5. We investigated the influence of CYP3A5 polymorphism and concurrent use of azole antifungal agents (AZ) on the pharmacokinetics of a once-daily modified-release tacrolimus formulation (Tac-QD) in patients after hematopoietic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Chemother Pharmacol
Autors principals: Yamashita, Takaya, Fujishima, Naohito, Miura, Masatomo, Niioka, Takenori, Abumiya, Maiko, Shinohara, Yoshinori, Ubukawa, Kumi, Nara, Miho, Fujishima, Masumi, Kameoka, Yoshihiro, Tagawa, Hiroyuki, Hirokawa, Makoto, Takahashi, Naoto
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4921119/
https://ncbi.nlm.nih.gov/pubmed/27217047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3060-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars